Though some areas of SENS, such as stem cells and amyloid immunotherapy, are sufficiently mainstream not to need funding, most are still relative backwaters that rely on the Methuselah Foundation to progress. As a result of the great generosity of donors, the non-profit organization trebled the diversity of its research in 2008. At the BIL unconference in February, Chief Science Officer Aubrey de Grey gave an overview of the research projects that the organization is now funding, their significance to SENS, and their potential to lead to accelerated progress towards the defeat of aging in 2009 and beyond.
